Clinical Trial Uses New Technology for Breast Cancer Screening
A large National Cancer Institute-funded clinical trial to answer important questions about 2-D versus 3-D mammography is open and recruiting women in clinics across the United States and in Canada. The Tomosynthesis Mammographic Imaging Screening Trial, known as TMIST, needs 165,000 women ages 45 to 74 to compare the current standard for mammograms (digital 2-D mammography) to tomosynthesis (3-D mammography) and is being headed by Etta Pisano, M.D., and the ECOG-ACRIN clinical trials group. The trial will answer whether the newer technology will reduce the rates of life-threatening breast cancers. Women enrolled in TMIST are randomly assigned to tomosynthesis or 2D mammography, and most will be screening once a year for 5 years; some post-menopausal women without additional risk will be screened every other year. There is funding available for uninsured women who wish to participate in TMIST. For more information, visit the TMIST study website.
No hay comentarios:
Publicar un comentario